secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2022-06-01T23:59:59+00:00
Accession:  0001104659-22-066896
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio CEO Bruce Goldsmith steps down; Chip Cale named interim CEO, Maxine Gowen interim Executive Chair
--------------------------------------------------------------------------------

- Bruce Goldsmith ceases as CEO and director May 31, 2022; will serve as non-employee advisor through Sep 1, 2022 at $50k/month.
- Goldsmith receives severance: $566,500 lump sum, COBRA for 12 months, pro-rata 2022 bonus, 100,000-share option at $1.86.
- Chip Cale (General Counsel) appointed Interim CEO and President; base salary increased $15k/month, 100,000-share option at $1.80 vesting over 12 months.
- Maxine Gowen appointed Interim Executive Chair; receives $20k/month and 40,000-share option at $1.80 vesting over 12 months.
- May 26, 2022 annual meeting: Gowen and Woiwode re-elected as Class II directors; KPMG ratified as auditor for 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000110465922066896/0001104659-22-066896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000110465922066896/tm2217427d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-066896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer